Diabetes Type 2

Multimorbidity was associated with a 63% increased risk for dementia among adults older than age 60 years followed for up to 15 years.

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.

New survey findings suggest the need for more in-depth conversations with patients about benefits and harms of newer oral therapies for type 2 diabetes.

Hospital admissions among patients with T2D taking basal insulin only were reduced by 67% one year after beginning treatment with the CGM system.

Semaglutide prescribed in clinical practice helped more than half of study participants achieve weight loss of ≥10% at 6 months.

Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.

Nocturnal HTN is a risk factor for cardiovascular disease and stroke. How do you diagnose and treat in your practice? Test your overnight BP IQ.

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.

A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.

Blood pressure-lowering therapy reduced the risk of major CV events in persons with and without type 2 diabetes, according to an individual participant-level data meta-analysis.